Companies › NeuShen Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Other; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NS-079 | – | Phase 1 | Healthy Adult Participants | Feb 2027 |
| NS-136 | – | Phase 1 | Healthy Subjects | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06345703 | NS-136 | Phase 1 | Healthy Subjects | Other | Nov 2024 |
| NCT07669571 | NS-079 | Phase 1 | Healthy Adult Participants | Other | Feb 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.